Agenus (NASDAQ:AGEN) Stock Passes Above Two Hundred Day Moving Average - What's Next?

Agenus Inc. (NASDAQ:AGEN - Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.94 and traded as high as $4.53. Agenus shares last traded at $4.27, with a volume of 392,182 shares.

Analysts Set New Price Targets

AGEN has been the subject of a number of research analyst reports. Robert W. Baird increased their target price on shares of Agenus from $4.00 to $6.00 and gave the stock a "neutral" rating in a research report on Wednesday, June 4th. Wall Street Zen lowered shares of Agenus from a "buy" rating to a "hold" rating in a research report on Sunday, August 17th. Zacks Research raised shares of Agenus to a "hold" rating in a research report on Tuesday, August 12th. Finally, HC Wainwright reiterated a "buy" rating and issued a $23.00 price target on shares of Agenus in a report on Wednesday, September 10th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $14.50.

Agenus Stock Performance

The stock's fifty day moving average is $4.90 and its two-hundred day moving average is $3.94. The firm has a market capitalization of $136.04 million, a price-to-earnings ratio of -0.60 and a beta of 1.44.

Agenus (NASDAQ:AGEN - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.22). The company had revenue of $25.70 million for the quarter, compared to analyst estimates of $49.71 million. Sell-side analysts anticipate that Agenus Inc. will post -12.55 earnings per share for the current year.

Institutional Investors Weigh In On Agenus

A number of hedge funds have recently bought and sold shares of the business. Apollon Wealth Management LLC grew its stake in Agenus by 25.0% during the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 5,000 shares in the last quarter. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Agenus during the second quarter worth approximately $50,000. Jump Financial LLC acquired a new stake in shares of Agenus during the second quarter worth approximately $55,000. CWM LLC grew its position in shares of Agenus by 105.8% during the second quarter. CWM LLC now owns 26,246 shares of the biotechnology company's stock worth $120,000 after buying an additional 13,494 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Agenus by 32.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 63,685 shares of the biotechnology company's stock worth $96,000 after buying an additional 15,731 shares in the last quarter. Institutional investors and hedge funds own 61.46% of the company's stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.